| Literature DB >> 29720971 |
Tetiana Dumych1, Nao Yamakawa2, Adeline Sivignon3, Estelle Garenaux3, Stefania Robakiewicz2, Bernadette Coddeville2, Antonino Bongiovanni4, Fabrice Bray5, Nicolas Barnich3, Sabine Szunerits6, Christian Slomianny7, Martin Herrmann8, Sébastien G Gouin9, Alexander D Lutsyk1, Luis E Munoz8, Frank Lafont4, Christian Rolando5, Rostyslav Bilyy1, Julie M J Bouckaert2.
Abstract
A novel mechanism is revealed by which clinical isolates of adherent-invasive Escherichia coli (AIEC) penetrate into the epithelial cell layer, replicate, and establish biofilms in Crohn's disease. AIEC uses the FimH fimbrial adhesin to bind to oligomannose glycans on the surface of host cells. Oligomannose glycans exposed on early apoptotic cells are the preferred binding targets of AIEC, so apoptotic cells serve as potential entry points for bacteria into the epithelial cell layer. Thereafter, the bacteria propagate laterally in the epithelial intercellular spaces. We demonstrate oligomannosylation at two distinct sites of a glycoprotein receptor for AIEC, carcinoembryonic antigen related cell adhesion molecule 6 (CEACAM6 or CD66c), on human intestinal epithelia. After bacterial binding, FimH interacts with CEACAM6, which then clusters. The presence of the highest-affinity epitope for FimH, oligomannose-5, on CEACAM6 is demonstrated using LC-MS/MS. As mannose-dependent infections are abundant, this mechanism might also be used by other adherent-invasive pathogens.Entities:
Keywords: CEACAM6; Crohn's disease; adherent-invasive E. coli; apoptotic cell-derived membranous vesicles; oligomannose glycans
Year: 2018 PMID: 29720971 PMCID: PMC5915571 DOI: 10.3389/fmicb.2018.00742
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Figure 1Infection of HeLa cells with AIEC induces surface blebbing. (A) Video microscopy over a time course of several minutes, where AIEC that had been co-incubated for 6 h with HeLa cells attach to and then penetrate (arrow) into membranous vesicles of blebbing cells. (B) Co-incubation of HeLa cells with E. coli UTI89 cells resulted in the appearance of oligomannose-rich blebs, as visualized using NPL-FITC lectin in DIC and fluorescence microscopy (merged images). (C) Bleb formation in HeLa cells treated with the FimH protein was observed as early as 2 h after infection. DIC imaging is shown in the upper row and fluorescence microscopy with annexin V-FITC (green) and PI (red) in the two lower rows. Scale bar = 10 μm.
Figure 2FimH binds to ACMV-derived oligomannoside glycans. (A) FimH-induced blebs possess oligomannose-glycans, which are known FimH-binding targets, resemble the blebs (B) seen during early apoptosis induced by UV-B irradiation. (C) Western blot of FimH-induced blebs shows CEACAM6 and oligomannosidic residues detected by using antibodies and Narcissus pseudonarcissus lectin (NPL), respectively. (D) Flow cytometry of FimH binding to Caco-2 cells and their ACMV. Both apoptotic cells and ACMV are effectively bound by FimH-FITC lectin (positive population is colored green).
Figure 3Bacterial colonization of Caco-2 cells requires surface exposure of the oligomannose. Bacteria penetrate through the intercellular spaces and then invade the cells. Their binding is dependent on FimH-oligomannose interactions. Nuclear DNA was visualized with DAPI staining (blue) and cell membranes were stained with fluorescent wheat germ agglutinin (WGA-FITC) (green, A–D). E. coli was transformed with a plasmid encoding NIR-fluorescent protein TurboFP635 (red, A–D). (A) Semi-confluent uninfected Caco-2 cells. (B,C) Caco-2 cells infected with E. coli LF82 for 5 h and treated with gentamicin for 19 h. (D) Infection for 24 h with LF82 without gentamicin treatment. (E) Untreated cells. (F) Infection with E. coli LF82-ΔfimH. (G) Wild-type E.coli LF82 and (H) E.coli LF82 co-incubated with 500 nM of a thiazolylamine mannose-based inhibitor. (E–H) NPL-FITC was used to visualize oligomannosidic glycans (green, overlayed). Scale bar = 10 μm.
Figure 4AIEC LF82 preferentially binds ACMV from dying cells due to their high mannose content. (A) Fluorescent video microscopy of HeLa cells after 7 h of co-culture with AIEC. (B) Confocal microscopy of live Caco-2 cells induced to apoptosis by UV-B irradiation. ACMV rich in mannose glycans were visualized by NPL-FITC. The bacteria produced NIR-fluorescent protein TurboFP635. Scale bar = 5 μm.
Figure 5CEACAM6 is involved in the initial binding of AIEC. The CEACAM6 glycoprotein is produced and distributed in clusters (A) on the surface of viable cells and (B,C) on late apoptotic blebs or ACMV. (D) Structured illumination super-resolution microscopy of CEACAM6 clustering at the initial bacterial binding sites. (E,F) CEACAM6 forms clusters upon contact with the bacterial cells, or the FimH protein.
Figure 6Glycosylation analysis of CEACAM6 identified two oligomannose-bearing glycosylation sites serving as receptors for the bacterial adhesin FimH. (A) MALDI TOF/TOF N-glycosylation profile of CEACAM6 isolated from Caco-2 cells treated with IFN-γ. The asterisk indicates a polyhexose contamination. The symbol “o” means oxonium structures of each high mannose glycan structure. LC-MS/MS profiles of the glycopeptide either (B) from recombinant human CEACAM6 protein or (C) from CEACAM6 isolated from intestinal epithelial cells after exposure to AIEC LF82 bacteria. Peptides were found with cysteine modification, (B) carbamidomethyl or (C) propionamide. Typical N-glycosylation (Man5GlcNAc2) was detected. Infection was for 3 h at a multiplicity of infection of 100 bacteria/cell.
Presence of high mannose glycans on three different peptides.
| – | – | Man5 | 32.909 | 6445 | C (carbamidomethyl) | |
| Man6 | 32.851 | 6434 | C (propionamide) | |||
| Man7 | 32.934 | 6449 | C (propionamide) | |||
| – | – | Man5 | 33.219 | 6620 | C (carbamidomethyl) | |
| Man6 | 32.955 | 6572 | C (carbamidomethyl) | |||
| Man7 | 32.950 | 6571 | C (propionamide) | |||
| – | – | Man5 | 33.220 | 6538 | C (propionamide) | |
| Man6 | 32.809 | 6463 | C (carbamidomethyl) | |||
| 40.283 | 7041 | Man5 | 38.217 | 6709 | C (carbamidomethyl) | |
| Man6 | 37.915 | 6661 | C (carbamidomethyl) | |||
| Man7 | 37.561 | 6605 | C (carbamidomethyl) | |||
| Man8 | 37.391 | 6577 | C (carbamidomethyl) | |||
| Man9 | 37.379 | 6575 | C (carbamidomethyl) | |||
| 64.012 | 10872 | Man5 | 61.786 | 10515 | ||
| Man7 | 61.486 | 10467 | ||||
| – | – | Man6 | 67.165 | 12836 | M (oxi) 1(deami) | |
| Man7 | 67.044 | 12812 | M (oxi) 1(deami) | |||
| Man8 | 66.628 | 12732 | M (oxi) 2(deami) | |||
| – | – | Man6 | 67.461 | 12954 | M (oxi) 1(deami) | |
| Man7 | 64.396 | 12376 | M (oxi) 1(deami) | |||
| Man8 | 74.040 | 14199 | 2(deami) | |||
| – | – | Man6 | 67.465 | 12835 | M (oxi) 1(deami) | |
| Man7 | 67.111 | 12768 | M (oxi) 1(deami) | |||
| Man8 | 66.476 | 12642 | M (oxi) 2(deami) | |||
| 71.017 | 11999 | Man5 | 57.172 | 9769 | M(oxi) 1(deami) | |
| Man6 | 57.188 | 9771 | M(oxi) 1(deami) | |||
| Man7 | 57.697 | 9853 | M(oxi) | |||
| Man8 | 63.419 | 10776 | ||||
inGel, in-gel trypsin digestion; control, CEACAM6 isolated from non-infected cells; LF82, CEACAM6 isolated from LF82-infected cells; K12, CEACAM6 isolated from K12-infected cells; recombinant, recombinant human CEACAM6; eFASP, enhanced filter-aided sample preparation; Rt, retention time; Scan, scan number of MS/MS spectrum; Man, mannose; M, modification; oxi, oxidation; deami, deamidation (1 or 2 times on this peptide).